ArticleMultiple sclerosis and related disorders2025
Self-reported quality of life related to cognitive function and fatigue in adults with multiple sclerosis.
Article in Multiple sclerosis and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Desired clinic characteristics and unmet support needs for adults with multiple sclerosis: A cross-sectional survey.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCognitive dysfunction and fatigue are two common chronic symptoms associated with multiple sclerosis (MS) and have significant impacts on quality of life (QoL). Assessment for potentially modifiable factors associated with these symptoms is needed to improve outcomes and QoL.
methodsAn electronic survey was developed and distributed to adults with MS, assessing demographics, MS disease factors, socioeconomic status, and QoL related to cognitive function and fatigue using Neuro-QoL
results332 participants completed the survey, with a mean age of 52 years. They were predominantly female (80 %) and White (85 %). The mean years since MS diagnosis was 15.6 years, with 81 % starting disease-modifying therapy (DMT) within 1 year of diagnosis. In a fit reduced model, higher QoL related to cognitive function was associated with starting a DMT and completion of Bachelor's degree, while lower QoL was related to self-reported diagnosis of depression and ≥ 2 flares since DMT initiation. For fatigue, higher QoL was associated with greater duration of MS and completion of a Bachelor's degree, and lower QoL with depression, ≥ 2 flares since DMT initiation, and higher self-reported disability.
conclusionsIn this survey of adults with MS, quality of life related to cognitive function was higher in those starting any efficacy of DMT. Larger longitudinal clinical studies should evaluate the impact of modifiable clinical factors on quality of life related to cognitive function and fatigue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.